Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2765 EUR -0.36%
Market Cap: 32m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Cash from Operating Activities
-€15.8m
CAGR 3-Years
5%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash from Operating Activities
-€142.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Cash from Operating Activities
-€18.1m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
-4%
G
Genfit SA
PAR:GNFT
Cash from Operating Activities
-€41.5m
CAGR 3-Years
19%
CAGR 5-Years
10%
CAGR 10-Years
-12%
Inventiva SA
PAR:IVA
Cash from Operating Activities
-€84.7m
CAGR 3-Years
-25%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Operating Activities
€26.8m
CAGR 3-Years
-32%
CAGR 5-Years
68%
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
32m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.1634 EUR
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Cash from Operating Activities?
Cash from Operating Activities
-15.8m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Cash from Operating Activities amounts to -15.8m EUR.

What is Gensight Biologics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
15%

Over the last year, the Cash from Operating Activities growth was 53%. The average annual Cash from Operating Activities growth rates for Gensight Biologics SA have been 5% over the past three years , 15% over the past five years .

Back to Top